Nijdam A, Kurnik K, Liesner R, Ljung R, Nolan B, Petrini P, Fischer K
Van Creveldkliniek, University Medical Center, Utrecht, The Netherlands.
Dr. von Haunersches Children's Hospital, University of Munich, Munich, Germany.
Haemophilia. 2015 Jul;21(4):444-50. doi: 10.1111/hae.12613. Epub 2015 Jan 13.
To facilitate early prophylaxis, step-up regimens starting prophylaxis with infusions 1× week(-1) were introduced. Choice of initial regimen may affect outcome. This study aims to classify initial prophylactic regimens and compare them on short-term outcome. From the 'European Paediatric Network for Haemophilia Management' (PedNet) registry, patients with severe haemophilia A without inhibitors, born 2000-2012, receiving prophylaxis were included. Treatment centres were classified according to the initial frequency of prophylactic infusions and the age at reaching infusions ≥3× week(-1) . Bleeding, and central venous access device (CVAD) use were compared at age 4 years. In 21 centres with 363 patients, three regimens were identified: (i) start prophylaxis with ≥3× week(-1) infusions before age three (full: 19% of centres, 18% of patients); (ii) start 1-2× week(-1) , increasing frequency as soon as possible (asap), reaching ≥3× week(-1) before age three (43% of centres, 36% of patients); (iii) start 1-2× week(-1) , increasing frequency according to bleeding (phenotype), reaching ≥3× week(-1) after age three (38% of centres, 46% of patients). Prophylaxis was started at median 1.2 years on the full and asap regimen vs 1.8 years on the phenotype regimen. Complete prevention of joint bleeds was most effective on the full regimen (32% full vs. 27% asap and 8% phenotype), though at the cost of using most CVADs (88% full vs. 34% asap and 22% phenotype). The three prophylaxis regimens identified had different effects on early bleeding and CVAD use. This classification provides the first step towards establishing the optimum prophylactic regimen.
为促进早期预防,引入了从每周1次输注(-1)开始预防的强化方案。初始方案的选择可能会影响治疗结果。本研究旨在对初始预防方案进行分类,并比较它们的短期治疗结果。从“欧洲血友病管理儿科网络”(PedNet)登记处纳入了2000年至2012年出生、无抑制物且接受预防治疗的重度甲型血友病患者。治疗中心根据预防性输注的初始频率以及达到每周≥3次输注(-1)的年龄进行分类。在4岁时比较出血情况和中心静脉通路装置(CVAD)的使用情况。在21个中心的363例患者中,确定了三种方案:(i)在3岁前开始每周≥3次输注进行预防(全程方案:19%的中心,18%的患者);(ii)开始时每周1 - 2次输注(-1),尽快增加频率(尽快方案),在3岁前达到每周≥3次输注(-1)(43%的中心,36%的患者);(iii)开始时每周1 - 2次输注(-1),根据出血情况(表型)增加频率,在3岁后达到每周≥3次输注(-1)(38%的中心,46%的患者)。全程方案和尽快方案的预防治疗中位起始年龄为1.2岁,而表型方案为1.8岁。全程方案对关节出血的完全预防效果最佳(全程方案为32%,尽快方案为27%,表型方案为8%),不过代价是使用CVAD的比例最高(全程方案为88%,尽快方案为34%,表型方案为22%)。确定的三种预防方案对早期出血和CVAD使用有不同影响。这种分类为确定最佳预防方案迈出了第一步。